| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | gABRb3 |
| Uniprot No | P28472 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-473aa |
| 氨基酸序列 | MWGLAGGRLFGIFSAPVLVAVVCCAQSVNDPGNMSFVKETVDKLLKGYDIRLRPDFGGPPVCVGMNIDIASIDMVSEVNMDYTLTMYFQQYWRDKRLAYSGIPLNLTLDNRVADQLWVPDTYFLNDKKSFVHGVTVKNRMIRLHPDGTVLYGLRITTTAACMMDLRRYPLDEQNCTLEIESYGYTTDDIEFYWRGGDKAVTGVERIELPQFSIVEHRLVSRNVVFATGAYPRLSLSFRLKRNIGYFILQTYMPSILITILSWVSFWINYDASAARVALGITTVLTMTTINTHLRETLPKIPYVKAIDMYLMGCFVFVFLALLEYAFVNYIFFGRGPQRQKKLAEKTAKAKNDRSKSESNRVDAHGNILLTSLEVHNEMNEVSGGIGDTRNSAISFDNSGIQYRKQSMPREGHGRFLGDRSLPHKKTHLRRRSSQLKIKIPDLTDVNAIDRWSRIVFPFTFSLFNLVYWLYYVN |
| 预测分子量 | 54,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GABRB3重组蛋白的模拟参考文献示例(注：内容为示例性概括，实际文献需通过学术数据库查询)：
---
1. **文献名称**: *"Expression and pharmacological characterization of recombinant human GABAA receptor β3 subunit in HEK293 cells"*
**作者**: Hirose, S., et al.
**摘要**: 该研究在HEK293细胞中成功表达了重组人源GABAA受体β3亚基，并通过电生理学方法分析了其对GABA和苯二氮䓬类药物的响应。结果表明，β3亚基的特定结构域对受体通道的门控动力学具有关键作用。
2. **文献名称**: *"Structural insights into GABRB3 mutations associated with epilepsy syndromes"*
**作者**: Miller, P.S., et al.
**摘要**: 通过冷冻电镜技术解析了携带致病性突变(如p.Pro302His)的GABRB3重组蛋白结构，发现突变导致受体配体结合域构象改变，降低了GABA结合效率，可能与婴儿痉挛症发病相关。
3. **文献名称**: *"Functional impact of autism-linked GABRB3 variants on recombinant receptor trafficking"*
**作者**: Delahanty, R.J., et al.
**摘要**: 研究利用重组GABRB3蛋白结合荧光标记技术，发现自闭症相关突变(如R407C)会干扰受体向细胞膜转运的过程，导致突触抑制性信号传导缺陷。
4. **文献名称**: *"High-throughput screening of GABAAR β3-selective modulators using recombinant protein assays"*
**作者**: Simeone, X., et al.
**摘要**: 开发了一种基于重组GABRB3受体蛋白的高通量筛选平台，鉴定出新型β3亚基特异性激动剂，为靶向治疗焦虑和神经疼痛提供了潜在先导化合物。
---
**注意**：以上为模拟文献，实际研究中请通过PubMed、Web of Science或Google Scholar等平台检索真实文献(关键词：GABRB3 recombinant protein, GABA receptor beta3 subunit)。
**Background of GABRB3 Recombinant Protein**
The gamma-aminobutyric acid type A receptor beta 3 subunit (GABRB3) is a critical component of GABA_A receptors, ligand-gated ion channels responsible for mediating fast inhibitory neurotransmission in the central nervous system. These receptors are pentameric structures typically composed of combinations of α, β, γ, and other subunits. The β3 subunit, encoded by the *GABRB3* gene, plays a vital role in receptor assembly, synaptic localization, and chloride ion channel function. Dysregulation of GABRB3 expression or mutations in the gene have been linked to neurodevelopmental disorders, including Angelman syndrome, autism spectrum disorders (ASD), and epilepsy, underscoring its importance in maintaining neural excitability balance.
Recombinant GABRB3 protein is engineered using heterologous expression systems (e.g., HEK293 or insect cells) to produce purified β3 subunits for functional and structural studies. This protein retains key domains, such as the extracellular N-terminal ligand-binding region, four transmembrane helices, and intracellular loops involved in receptor trafficking and modulation. Researchers utilize recombinant GABRB3 to investigate GABA_A receptor pharmacology, screen therapeutic compounds targeting neuropsychiatric conditions, and study disease-associated mutations. For instance, studies have shown that certain β3 subunit variants alter receptor kinetics or surface expression, contributing to hyperexcitability phenotypes.
The development of GABRB3 recombinant proteins has advanced drug discovery and mechanistic insights into GABAergic signaling. Its applications extend to electrophysiology, cryo-EM studies for structural resolution, and generating disease models using CRISPR-edited variants. Continued research aims to refine targeted therapies for disorders linked to GABA_A receptor dysfunction, leveraging recombinant tools to bridge molecular insights with clinical outcomes.
×
